GLIA Diagnostics
Making the Invisible Injury Visible
GLIA Diagnostics (GLIA) is an Australian medtech company developing a platform intended to provide objective biological information following traumatic brain injury (TBI), including mild TBI (mTBI/concussion). Our clinically studied multiplex biomarker programme is being translated toward a rapid, portable point-of-care (PoC) platform.
Investigational technology in development. Not approved for commercial clinical use.
~20 min
Target sample-to-result time*
5 Human Studies / Cohorts
Across acute injury, mild TBI and recovery
7-Marker miRNA Panel
Multiplex circulating miRNA programme
4 Peer-Reviewed Publications
Human research evidence base
*Target sample-to-result time is a development objective and has not been validated in a clinical setting.
Who We Are
About Us
GLIA is an Australian medtech company translating a clinically studied multiplex miRNA biomarker programme into a portable PoC platform for traumatic brain injury (TBI). The intended system combines a biological sample, cartridge and a handheld reader, targeting an approximately 20-minute result. GLIA is currently rapidly progressing with integrated MVP development.
The Challenge
mTBI / concussion remain difficult to assess objectively — particularly when structural imaging is normal.
There remains an important unmet need for objective biological information that can complement clinical assessment closer to the PoC.
How It Works
A Rapid Molecular Workflow
01
Collect
A blood sample is collected at the PoC — designed for use in clinical, sport and austere settings.
02
Analyse
The sample is processed through GLIA's multiplex miRNA detection system targeting a panel of circulating biomarkers.
03
Inform
Designed to provide objective biological information alongside clinical assessment, with an approximately 20-minute target workflow.
One Platform
Designed for Where It Matters
GLIA is investigating potential applications across TBI assessment and longitudinal recovery, subject to further clinical validation and regulatory clearance.
Across clinical, sport and defence settings, the intended role is to provide complementary objective biological information alongside established assessment and TBI/concussion protocols.
Our Mission
Why It Matters & Our Technology
Why It Matters
Mild traumatic brain injury (mTBI/concussion) can be difficult to assess objectively, particularly when structural imaging is normal. GLIA is developing a platform intended to provide complementary biological information alongside established clinical assessment. Potential applications being investigated include acute assessment, prognosis and longitudinal recovery monitoring across clinical, sport, Defence and remote settings.
Proprietary microRNA Biomarkers
GLIA is investigating whether its clinically studied miRNA panel can provide complementary biological information relevant to injury response, prognosis, and longitudinal recovery.
PoC Platform
GLIA is developing a rapid, portable point-of-care platform intended to bring objective molecular information closer to the patient. The approximately 20-minute target workflow and intended applications remain subject to analytical, clinical and regulatory validation.
Regulatory & Clinical Validation
GLIA is advancing through rigorous development and validation pathways aligned to international regulatory standards.
Our Technology
Grounded in Rigorous Molecular Science
Multiplex miRNA Biomarker Programme
GLIA is investigating a circulating miRNA panel supported by human research across acute TBI, mild TBI and longitudinal recovery. The programme is being developed as a complementary molecular approach to brain-injury assessment.
PoC Platform
GLIA is translating its clinically studied biomarker programme toward a portable PoC system intended to bring objective molecular information closer to the patient.
Regulatory Pathway
GLIA is progressing regulatory planning for major international markets, including Australia, the United States and Europe. The final intended use and regulatory pathway remain subject to regulatory engagement and product validation.
Clinical Evidence
Building a Body of Evidence
GLIA’s biomarker programme is supported by four peer-reviewed human studies investigating circulating miRNA signals across acute injury, mild TBI, longitudinal recovery and persistent symptoms. This evidence supports continued translation and prospective validation of the GLIA platform.
Human Evidence
Five human studies/cohorts across acute injury, mild TBI, recovery and other relevant settings.
4 Peer-Reviewed Publications
Published human research investigating TBI-associated circulating miRNA signals and longitudinal biology.
Multi-Marker Panel
A multiplex circulating miRNA panel selected through GLIA’s research and IP programme.
Development Roadmap
Advancing From Research to PoC
Clinical Foundation
Human biomarker research, peer-reviewed publications and IP established.
Product Translation — Underway
Translation of the biomarker programme toward an integrated portable PoC platform.
Validation & Regulatory Development
Further analytical and clinical validation, regulatory engagement and commercialisation planning.
Commercial Milestones
Progress From Research to Product Translation
Founded 2015
Four peer-reviewed human publications
International IP portfolio
Australian and US research engagement
PoC development underway
Regulatory planning underway
Competitive Advantage
A Differentiated Position for Translation
GLIA combines a clinically studied multiplex miRNA biomarker programme, an international IP portfolio and PoC technology development. The platform is being investigated as a complementary molecular approach to objective TBI assessment and longitudinal biological monitoring.
Granted Patents
International patent families granted across key jurisdictions.
Proprietary PoC IP
GLIA-owned IP covering PoC technology development.
Global IP Portfolio
Three Patent Families — Granted and Pending
GLIA holds licensed biomarker IP and GLIA-owned patent families covering TBI diagnostics, PoC technology and diagnostic methods.
GLIA #1 — TBI Biomarker IP
GrantedGLIA #2 — PoC Technology
Patent PendingGLIA #3 — Diagnostic & Prognostic Methods
Patent PendingFurther IP information is available to prospective partners and investors.
The Competitive Landscape
Comparing Today’s Technologies
Current TBI assessment uses a combination of clinical examination, imaging and, increasingly, objective diagnostic technologies. Each addresses a different part of the care pathway. GLIA is investigating whether multiplex circulating miRNA can provide complementary biological information following brain injury and across recovery.
Clinical Assessment
Essential to concussion/TBI evaluation and management.
Structural Imaging
Important for identifying structural injury but not a stand-alone test for concussion.
Blood-Based Biomarkers
An emerging objective diagnostic category with established regulatory precedent in acute TBI assessment.
The GLIA Difference
What Sets GLIA Apart
Multiplex molecular approach — investigating circulating miRNA biology associated with brain injury and recovery.
Point-of-care ambition — translating the biomarker programme toward a portable near-patient platform.
Longitudinal potential — investigating biological information beyond a single point in time.
Complementary by design — intended to sit alongside clinical assessment and established TBI pathways.
Research, Development and Engagement Network
Built on Credible Partnerships
The Alfred Hospital
Macquarie University
Australian & US Defence — Research engagement
US Professional Sport — Research and study engagement
CSIRO
Where It Matters
Applications Across High-Need Settings
Sport & Athletics
Being investigated to provide objective biological information following suspected concussion and across recovery, alongside established clinical assessment and concussion protocols.
Military & Defence
Being investigated for objective biological assessment following blast or other head-injury exposure, including longitudinal research in operationally relevant settings.
Investors & Industry
Partner With GLIA
GLIA welcomes engagement with strategic diagnostic partners, research collaborators, investors and organisations interested in advancing objective brain-injury assessment and monitoring.
Get in TouchWatch
GLIA Diagnostics: TBI Diagnostics Overview
This video provides an overview of GLIA’s TBI diagnostic research and development programme.
References
- 1.
Hicks SD, et al. Diagnosing mild traumatic brain injury using saliva: a pilot study. J Neurotrauma. 2018;35(1):159-166.
- 2.
Hicks SD, et al. Serum microRNA signatures identify traumatic brain injury in a mouse model. J Neurotrauma. 2010;27(7):1295-1306.
- 3.
Mitra B et al. Plasma micro-RNA biomarkers for diagnosis and prognosis after traumatic brain injury: A pilot study. J Clin Neurosci. 2017. https://doi.org/10.1016/j.jocn.2016.12.009
- 4.
Mitra B et al. Micro-RNA levels and symptom profile after mild traumatic brain injury: A longitudinal cohort study. J Clin Neurosci. 2022. https://doi.org/10.1016/j.jocn.2021.11.021
- 5.
Mitra B et al. MicroRNA biomarkers for diagnosis of mild traumatic brain injury and prediction of persistent symptoms: A prospective cohort study. J Clin Neurosci. 2023. https://doi.org/10.1016/j.jocn.2023.07.011
- 6.
Mitra B et al. MicroRNA Biomarkers on Day of Injury Among Patients with Post Concussive Symptoms at 28-Days: A Prospective Cohort Study. J Clin Neurosci. 2024. https://doi.org/10.2174/0122115366297817240613065052
Subscribe
Sign up to hear from us.
Get in Touch
Contact Us
GLIA Diagnostics Pty Ltd
Mosman, New South Wales, Australia